Australia markets close in 24 minutes

Monopar Therapeutics Inc. (MNPR)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.7550-0.0260 (-3.33%)
At close: 04:00PM EDT
0.7312 -0.02 (-3.15%)
After hours: 05:45PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.7810
Open0.7510
Bid0.7296 x 100
Ask0.7674 x 100
Day's range0.7500 - 0.7810
52-week range0.2740 - 1.7500
Volume101,441
Avg. volume5,498,793
Market cap13.632M
Beta (5Y monthly)1.20
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

    WILMETTE, Ill., April 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its Phase 1 dosimetry clinical trial for its novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) is now active and recruiting patients with advanced cancers. The antibody MNPR-101 targets the urokinase plasminogen activator receptor (uPAR),

  • GlobeNewswire

    Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

    WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments. Recent Developments Novel MNPR-101 Radiopharmaceutical Program targeting uPAR – Phase 1 dosimetry clinical trial to commence in the coming weeks MNPR-101-Zr Phase 1 dosimetry clinical trial has H

  • GlobeNewswire

    Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

    FIgure 1 Biodistribution of Therapeutic Radioisotope Lu-177 Conjugated to MNPR-101 in Pancreatic Cancer (MIA PaCa-2) Tumor Xenograft WILMETTE, Ill., March 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced positive preclinical imaging data of a therapeutic radioisotope bound to its proprietary uPAR (urokinase plasminogen activator receptor) targeting age